Loading stock data…
ABVX
$122.13-0.61 (-0.50%)
Market ClosedLast close May 11
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ABIVAX Société Anonyme in the Healthcare sector is trading at $122.13. The stock is currently near its 52-week high of $148.83, remaining 15.3% above its 200-day moving average. Technical signals show neutral RSI of 62 and bullish MACD crossover, explaining why ABVX maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 62) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$122.13
Potential Upside
5%
Whystock Fair Value$128.24
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$155.20+27.1%
Range$131.00 – $176.00
Fundamentals
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate inclu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.44B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.10
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-73.84%
Volume
Today's trading volume
677,803
Recent News
ABIVAX (ABVX) Announces $90M Agreement to Repurchase Royalty Certificates
ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the best young stocks to buy and hold for the next decade. On May 5, ABIVAX announced a $90 million agreement to repurchase and cancel all royalty certificates issued in September 2022. The transaction will be funded through a combination of $45 million in cash and a $45 […]
Here is Why Abivax (ABVX) is One of the Best Up and Coming Stocks with Highest Upside Potential
ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the best up and coming stocks with highest upside potential. On March 23, Abivax reported its full-year 2025 financial results, highlighting steady clinical progress for its lead drug candidate, obefazimod. Following a major $700.3 million public offering in July 2025, the company ended the year with €530.4 million […]
Bright Prospects Ahead for Abivax (ABVX)
Michigan-based investment advisor Cedar Grove Capital Management recently released its first quarter 2026 investor letter. A copy of the letter can be downloaded here. Cedar Grove Capital Management’s Multi-Strategy Composite posted a -23.0% net return since inception, compared to -5.6% for the Russell 2000, -5.9% for the Russell Microcap, and -5.5% for the S&P 500. […]
ABIVAX (ABVX) Appoints Michael Nesrallah as Chief Commercial Officer
ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the 7 Best Strong Buy European Stocks to Invest In. On April 2, 2026, ABIVAX Société Anonyme (NASDAQ:ABVX) appointed Michael Nesrallah as chief commercial officer. Michael Nesrallah will lead global commercial strategy and launch preparation for obefazimod as the company moves toward potential regulatory approval, bringing more than […]
This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy?
We'll soon know more about the drugmaker's long-term prospects.